Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib

J Thorac Oncol. 2019 Dec;14(12):e266-e268. doi: 10.1016/j.jtho.2019.07.021.

Authors

Jing Luo¹, Dejian Gu², Huasong Lu¹, Si Liu¹, Jinliang Kong³

Affiliations

¹ Pulmonary and Critical Care Medicine Ward, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
² Geneplus-Beijing Ltd., Beijing, China.
³ Pulmonary and Critical Care Medicine Ward, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. Electronic address: [email protected].

PMID: 31757376
DOI: 10.1016/j.jtho.2019.07.021

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics
Adenocarcinoma of Lung / pathology
Anaplastic Lymphoma Kinase / genetics*
Antineoplastic Agents / therapeutic use
Crizotinib / therapeutic use*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics*
Lung Neoplasms / pathology
Male
Middle Aged
Oncogene Proteins, Fusion / genetics*
Protein Kinase C beta / genetics*

Substances

Antineoplastic Agents
EML4-ALK fusion protein, human
Oncogene Proteins, Fusion
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase
PRKCB protein, human
Protein Kinase C beta